Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla, Sanjeev; Maclennan, Gregory T; Hartman, Douglas J; Fu, Pingfu; Resnick, Martin I; Gupta, Sanjay; ; 2007-06-07
Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt/PKB are important signaling ... PI3K-Akt signaling pathway in the invasion of prostate cancer cell lines and activation of this pathway in primary human prostate
International journal of cancer. Journal international du cancer
PubMed Database
2 Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.
Giovannucci, Edward; Liu, Yan; Platz, Elizabeth A; Stampfer, Meir J; Willett, Walter C; ; 2007-04-24
Risk factors for prostate cancer could differ for various sub-groups, such as for "aggressive" and "non-aggressive" cancers or by grade or stage. Determinants of mortality could differ from those for incidence.
International journal of cancer. Journal international du cancer
PubMed Database
3 Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-A new paradigm for cooperation among prostate tumor cells.
Lapouge, Gaëlle; Erdmann, Eva; Marcias, Gemma; Jagla, Monika; Monge, Audrey; Kessler, Pascal; Serra, Sebastian; Lang, Hervé; Jacqmin, Didier; Bergerat, Jean-Pierre; Céraline, Jocelyn; ; 2007-05-31
The emergence of mutations in the androgen receptor (AR) gene is a recurrent event during progression of prostate cancer (PCa) on androgen ablation therapy. In this study, we show that nonsense mutations that lead to carboxyl-terminal end ...
International journal of cancer. Journal international du cancer
PubMed Database
4 Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
Gonzalez-Moreno, Oscar; Segura, Victor; Serrano, Diego; Nguewa, Paul; de Las Rivas, Javier; Calvo, Alfonso; ; 2007-05-24
New therapeutic agents are needed for the treatment of androgen-independent prostate cancer (PrCa). ... methylseleninic acid (MSA) on tumor stage-specific prostate cells derived from the C3 (1)/Tag model for PrCa: Pr111, a slow-growing ...
International journal of cancer. Journal international du cancer
PubMed Database
5 Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition.
Travis, Ruth C; Key, Timothy J; Allen, Naomi E; Appleby, Paul N; Roddam, Andrew W; Rinaldi, Sabina; Egevad, Lars; Gann, Peter H; Rohrmann, Sabine; Linseisen, Jakob; Pischon, Tobias; Boeing, Heiner; Johnsen, Nina Føns; Tjønneland, Anne; Overvad, Kim; Kiem...; 2007-05-22
We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested ... European Prospective Investigation into Cancer ...
International journal of cancer. Journal international du cancer
PubMed Database
6 Fat and meat intake and prostate cancer risk: The multiethnic cohort study.
Park, Song-Yi; Murphy, Suzanne P; Wilkens, Lynne R; Henderson, Brian E; Kolonel, Laurence N; ; 2007-05-10
Dietary fat and meat as potential risk factors for prostate cancer have been the focus of many epidemiologic investigations, and findings from recent studies in particular have been inconsistent. ... association between these exposures and ...
International journal of cancer. Journal international du cancer
PubMed Database
7 Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D(3) derivative in prostate cancer cells.
Lambert, James R; Young, Christian D; Persons, Kelly S; Ray, Rahul; ; 2007-07-31
... has strong antiproliferative effects in cancer cells. But it is highly toxic at therapeutic doses. We have observed that 25-hydroxyvitamin D(3)-3-bromoacetate (25-OH-D(3)-3-BE), a derivative of 25-hydroxyvitamin ... prostate cancer cells.
Biochemical and biophysical research communications
PubMed Database
8 Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Bellmunt, Joaquim; Albiol, Santiago; Albanell, Joan; ; 2007-08-03
BJU international
PubMed Database
9 Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.
Hayes, Julia H; Barry, Michael J; Kantoff, Philip W; Stahl, James E; ; 2007-08-03
BJU international
PubMed Database
10 An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
Dudderidge, Tim; Payne, Heather; Emberton, Mark; ; 2007-06-19
OBJECTIVE To present a management algorithm for men with prostate cancer recurring after external beam radiotherapy (EBRT), based on a review of published reports, to assist clinicians in identifying
BJU international
PubMed Database
11 Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Sella, Avishay; Sternberg, Cora; Kovel, Svetlana; Yarom, Nirit; Skoneczna, Iwona; ; 2007-06-15
OBJECTIVE To assess the clinical pattern of progression and prostate-specific antigen doubling time (PSA-DT) after exposure ... cancer (AIPC). PATIENTS AND METHODS Fifty-five patients received docetaxel-based chemotherapy; data were collected ...
BJU international
PubMed Database
12 The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
Roddam, Andrew W; Hamdy, Freddie C; Allen, Naomi E; Price, Christopher P; for the UK Prostate Cancer Risk Management Programme ; 2007-06-05
OBJECTIVE To assess the effects on the performance characteristics, in a prostate-cancer detection programme using prostate-specific antigen (PSA) levels, of a lower PSA threshold and the incorporation of reflex (free or complexed ...
BJU international
PubMed Database
13 Bad expression influences time to androgen escape in prostate cancer.
Teo, Katy; Gemmell, Lisa; Mukherjee, Rono; Traynor, Pamela; Edwards, Joanne; ; 2007-06-05
OBJECTIVE To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation ... is the treatment of choice in advanced prostate ...
BJU international
PubMed Database
14 Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
Shimizu, Yousuke; Segawa, Takehiko; Inoue, Takahiro; Shiraishi, Taizo; Yoshida, Toru; Toda, Yoshinobu; Yamada, Tomomi; Kinukawa, Naoko; Terada, Naoki; Kobayashi, Takashi; Kinoshita, Hidefumi; Kamoto, Toshiyuki; Nakamura, Eijiro; Ogawa, Osamu; ; 2007-06-05
OBJECTIVE To investigate the relationship between the expression of Akt (a serine/threonine kinase that plays a central role in tumorigenesis), phosphorylated Akt (p-Akt), prostate cancer tumour grade, androgen receptor (AR)-staining score, ...
BJU international
PubMed Database
15 A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'.
Parker, Chris; ; 2007-05-31
BJU international
PubMed Database
16 Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin.
Li, Hongzhen; Kapur, Aneesh; Yang, Jesse X; Srivastava, Shiv; McLeod, David G; Paredes-Guzman, Julio F; Daugsch, Andreas; Park, Yong K; Rhim, Johng S; ; 2007-08-03
Propolis is a resinous substance collected by bees (Apis mellifera) from ... dracunculifolia), and propolis group 3 on proliferation of metastasis (DU145 and PC-3) and primary malignant tumor (RC58T/h/SA#4)-derived human prostate cancer cells.
International journal of oncology
PubMed Database
17 Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells.
Harada, Naoki; Yasunaga, Ryoko; Higashimura, Yasuki; Yamaji, Ryoichi; Fujimoto, Katsumi; Moss, Joel; Inui, Hiroshi; Nakano, Yoshihisa; ; 2007-06-08
Androgen receptor (AR) functions as a transcriptional factor for genes involved in proliferation and differentiation of normal and cancerous prostate cells. Coactivators that bind to AR are required for maximal androgen action.
The Journal of biological chemistry
PubMed Database
18 HPLC for stress-free screening of potential prostate cancer marker catechol estrogens in urine using a diamond-electrode electrochemical and a fluorescence detector.
Katayama, Masatoki Takamatsu, Kiyoshi Kaneko, Satoru Miyaji, Keisuke Ishikawa, Hiromichi Matsuda, Yoshifumi ; 2007-08-03
Improvement of the sensitivity and specificity of a simultaneous stress-free screening method for catechol estrogens as a potential prostate cancer marker ... the sensitivity and specificity of the prostatic
PubMed Database
19 Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins, Scott A; Laxman, Bharathi; Dhanasekaran, Saravana M; Helgeson, Beth E; Cao, Xuhong; Morris, David S; Menon, Anjana; Jing, Xiaojun; Cao, Qi; Han, Bo; Yu, Jindan; Wang, Lei; Montie, James E; Rubin, Mark A; Pienta, Kenneth J; Roulston, Diane; Shah,...; 2007-08-03
Recently, we identified recurrent gene fusions involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers.
Nature
PubMed Database
20 cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis.
Wu, D; Zhau, H E; Huang, W-C; Iqbal, S; Habib, F K; Sartor, O; Cvitanovic, L; Marshall, F F; Xu, Z; Chung, L W K; ; 2007-02-22
Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP-responsive element-binding protein (CREB) ...
Oncogene
PubMed Database
21 A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients.
Klabunde, Carrie N Legler, Julie M Warren, Joan L Baldwin, Laura-Mae Schrag, Deborah ; 2007-05-29
PURPOSE: We evaluated (i) how combining comorbid conditions identified from Medicare inpatient or physician ... linked database, from which four cohorts of cancer patients were derived: breast (n = 26,377), prostate (n = 53,503), colorectal (n
PubMed Database
22 Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
Lee, Dong I; Sumbilla, Carlota; Lee, Myounghee; Natesavelalar, Chidambaram; Klein, Michael G; Ross, Douglas D; Inesi, Giuseppe; Hussain, Arif; ; 2007-05-04
Cells with increasing resistance to the sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) inhibitor thapsigargin (TG), ranging from 60-fold (PC3/TG(10) cells) ... Thus, novel TG-specific resistance mechanisms are recruited by these cancer cells.
Archives of biochemistry and biophysics
PubMed Database
23 Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer.
Dieli, Francesco; Vermijlen, David; Fulfaro, Fabio; Caccamo, Nadia; Meraviglia, Serena; Cicero, Giuseppe; Roberts, Andrew; Buccheri, Simona; D'Asaro, Matilde; Gebbia, Nicola; Salerno, Alfredo; Eberl, Matthias; Hayday, Adrian C; ; 2007-08-03
The increasing evidence that gammadelta T cells have potent antitumor activity suggests ... trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the gammadelta T-cell agonist zoledronate,
Cancer research
PubMed Database
24 Guggulsterone-Induced Apoptosis in Human Prostate Cancer Cells Is Caused by Reactive Oxygen Intermediate Dependent Activation of c-Jun NH2-Terminal Kinase.
Singh, Shivendra V; Choi, Sunga; Zeng, Yan; Hahm, Eun-Ryeong; Xiao, Dong; ; 2007-08-03
Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, causes apoptosis in cancer cells but ... We now show that guggulsterone-induced cell death in human prostate cancer cells is caused by reactive oxygen intermediate (ROI)-dependent activation of c-Jun NH(2)-terminal kinase (JNK).
Cancer research
PubMed Database
25 Tendon abnormalities mimicking metastatic disease in patients with prostate cancer.
Kerimoglu, Ulku; Kaya, Diana; Ergen, Fatma Bilge; ; 2007-08-02
We present plain x-ray examination, bone scintigraphy, computed tomography, and magnetic resonance imaging of 2 patients diagnosed with prostate cancer who complained of hip pain. Bone scintigraphy was suggestive for metastases.
Clinical nuclear medicine
PubMed Database
26 Blood biomarkers for prostate cancer detection and prognosis.
Shariat, Shahrokh F Karam, Jose A Roehrborn, Claus G ; 2007-07-31
Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s.
PubMed Database
27 Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor.
Pickles, Tom; ; 2007-07-31
Evaluation of: Freedland SJ, Humphreys EB, Mangold LA et al.: Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause ...
Future oncology (London, England)
PubMed Database
28 Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure.
Jackson, Crystal L; Dreaden, Tina M; Theobald, Lisa K; Tran, Nhien M; Beal, Tiffany L; Eid, Manal; Gao, Mu Yun; Shirley, Robert B; Stoffel, Mark T; Kumar, M Vijay; Mohnen, Debra; ; 2007-05-22
Treatment options for androgen-independent prostate cancer cells are limited. Therefore, it is critical to identify agents that induce death of both androgen-responsive and androgen-insensitive cells.
Glycobiology
PubMed Database
29 Stem cells in prostate cancer initiation and progression.
Lawson, Devon A; Witte, Owen N; ; 2007-08-03
... paradigm shift in our understanding of cancer as a disease of stem cells. This Review focuses on the application of these concepts to investigation of the role of stem cells in prostate cancer initiation and progression.
The Journal of clinical investigation
PubMed Database
30 Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai, Tommaso; Bartoletti, Riccardo; ; 2007-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed Database
31 Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer.
Brown, Duncan J F; McArthur, Dorothy; Moulsdale, Helen; ; 2007-07-03
Journal of pain and symptom management
PubMed Database
32 Prostate cancer screening an individual decision.
Holcomb, Susan Simmons; ; 2007-08-02
The Nurse practitioner
PubMed Database
33 [Imaging procedures to diagnose prostate cancer.]
Seitz, M Scher, B Scherr, M Tilki, D Schlenker, B Gratzke, C Schipf, A Stanislaus, P Müller-Lisse, U Reich, O Stief, C ; 2007-08-01
Prostate cancer is one of the most frequent malignant diseases in men. ... progress achieved in imaging procedures, prostate biopsy is the gold standard for diagnosing prostate cancer.
PubMed Database
34 Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer.
Tam, L; McGlynn, L M; Traynor, P; Mukherjee, R; Bartlett, J M S; Edwards, J; ; 2007-06-28
The main cause of prostate cancer-related mortality is the development of hormone-refractory disease. ... IL-6 are raised in hormone-refractory prostate cancer patients and evidence from cell line studies suggests that the ...
British journal of cancer
PubMed Database
35 Association between FAS polymorphism and prostate cancer development.
Lima, L Morais, A Lobo, F Calais-da-Silva, F M Calais-da-Silva, F E Medeiros, R ; 2007-08-02
The role of FAS polymorphisms in prostate cancer has not been studied. ... -670 genotypes in DNA from 904 men: 657 prostate ... inhibition caused by the soluble form.Prostate Cancer and Prostatic Diseases
PubMed Database
36 Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
Halabi, Susan Ou, San-San Vogelzang, Nicholas J Small, Eric J ; 2007-08-01
BACKGROUND.: Obesity has a variety of adverse health outcomes, but to the authors' knowledge, the effect of obesity on outcome in patients with advanced prostate cancer is not known. ... with metastatic, castration-recurrent prostate ...
PubMed Database
37 A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Gross, Mitchell Higano, Celestia Pantuck, Allan Castellanos, Olga Green, Erica Nguyen, Koo Agus, David B ; 2007-07-31
ABSTRACT: BACKGROUND: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). ... toxicity of cytotoxic chemotherapy for prostate cancer.
PubMed Database
38 Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal, Christopher S Gore, John L Krupski, Tracey L Hanley, Janet Schonlau, Matthias Litwin, Mark S And the Urologic Diseases in America Project ; 2007-07-28
BACKGROUND.: The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. ... common reason for death among men with prostate cancer who do not die of the disease itself, data ...
PubMed Database
39 The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy.
Vickers, Andrew J Ulmert, David Serio, Angel M Björk, Thomas Scardino, Peter T Eastham, James A Berglund, Göran Lilja, Hans ; 2007-07-28
Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of ... fPSA, tPSA and hK2 were measured in archived plasma collected during 1974-1986 in 501 men subsequently diagnosed with prostate cancer up to 1999 and in 1,292 matched controls.
PubMed Database
40 The androgen receptor and prostate cancer: A role for sexual selection and sexual conflict?
Summers, Kyle Crespi, Bernard ; 2007-07-28
We propose and evaluate the hypothesis that the CAG repeat region of the androgen receptor represents a locus ... However, short repeats are also associated with increased risk of prostate cancer, and with more aggressive forms of the disease.
PubMed Database
41 IS OBESITY A RISK FACTOR FOR PROSTATE CANCER?
Goldstraw, Miles A Besrani, Dler Amoroso, Peter Kirby, Roger S ; 2007-07-31
PubMed Database
42 Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients.
Ismail, Mohamed Ahmed, Shwan Kastner, Christof Davies, John ; 2007-07-31
OBJECTIVE To report the short- to intermediate-term experience of using salvage targeted cryoablation of the prostate (TCAP) for the recurrence of localized prostate cancer after radiotherapy.
PubMed Database
43 The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod, Laurent Hammerer, Peter Madersbacher, Stephan Mottet, Nicolas Prayer-Galetti, Tommaso Tunn, Ulf ; 2007-07-31
PubMed Database
44 Targeting uPA/uPAR in prostate cancer.
Li, Y Cozzi, P J ; 2007-07-31
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease ...
PubMed Database
45 PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer.
Ganzer, Roman Rogenhofer, Sebastian Walter, Bernhard Lunz, Jens-Claudio Schostak, Martin Wieland, Wolf F Blana, Andreas ; 2007-07-31
OBJECTIVES: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free ... (Ablatherm((R)), EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively.
PubMed Database
46 Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.
Doak, Shareen H; Jenkins, Spencer A; Hurle, Rhidian A; Varma, Murali; Hawizy, Azad; Kynaston, Howard G; Parry, James M; ; 2007-07-28
Abnormal expression of bone morphogenic proteins (BMP) has been reported in prostate cancer as compared to benign prostatic tissue. ... this possibility in patients with early prostate cancer.
Cancer genetics and cytogenetics
PubMed Database
47 Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
Gudmundsson, Julius; Sulem, Patrick; Steinthorsdottir, Valgerdur; Bergthorsson, Jon T; Thorleifsson, Gudmar; Manolescu, Andrei; Rafnar, Thorunn; Gudbjartsson, Daniel; Agnarsson, Bjarni A; Baker, Adam; Sigurdsson, Asgeir; Benediktsdottir, Kristrun R; Jako...; 2007-07-03
We performed a genome-wide association scan to search for sequence variants conferring risk of prostate cancer using 1,501 Icelandic men with prostate cancer and 11,290 controls. Follow-up studies involving three additional ...
Nature genetics
PubMed Database
48 Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.
Pickles, Tom Ruether, J Dean Weir, Lorna Carlson, Linda Jakulj, Fabijana the SCRN Communication Team† ; 2007-05-30
OBJECTIVES To review the psychosocial needs of men undergoing active surveillance (AS, the monitoring of early prostate cancer, with curative intervention only if the disease significantly progresses) for prostate cancer, ...
PubMed Database
49 Does active surveillance for men with localized prostate cancer carry psychological morbidity?
Burnet, Katriina L; Parker, Chris; Dearnaley, David; Brewin, Chris R; Watson, Maggie; ; 2007-06-07
OBJECTIVES To investigate, in a cross-sectional study, the prevalence of anxiety and depression in patients with localised prostate cancer managed by active surveillance, compared with those receiving immediate treatment, as active surveillance ...
BJU international
PubMed Database
50 Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
Briganti, Alberto; Shariat, Shahrokh F; Chun, Felix K-H; Hutterer, Georg C; Roehrborn, Claus G; Gallina, Andrea; Rigatti, Patrizio; Valiquette, Luc; Montorsi, Francesco; Karakiewicz, Pierre I; ; 2007-06-19
OBJECTIVE To test whether the rate of lymph node invasion (LNI) differs ... PATIENTS AND METHODS In all, 1385 men had RP with bilateral lymphadenectomy for clinically localized prostate cancer (587 from Dallas, Texas and 798 from Milan, Italy).
BJU international
PubMed Database
51 Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano, Giuseppe; De Braud, Filippo; Teresa Sandri, Maria; Renne, Giuseppe; Zorzino, Laura; Scardino, Epifanio; Rocco, Bernardo; Spitaleri, Gianluca; De Pas, Tommaso; Noberasco, Cristina; Nolè, Franco; Verweij, Fabrizio; Matei, Victor; De Cobelli, Ot...; 2007-08-02
We investigated efficacy of gefitinib in hormone-refractory prostate cancer. ... 2004, 23 patients with hormone-refractory prostate cancer were assigned to receive 250 mg oral gefitinib daily in addition to antiandrogen and ...
Anti-cancer drugs
PubMed Database
52 Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling.
Yang, Yang; Ikezoe, Takayuki; Zheng, Zhixing; Taguchi, Hirokuni; Koeffler, H Phillip; Zhu, Wei-Guo; ; 2007-08-03
PC-SPES is an eight-herb mixture that has an activity against prostate cancer. ... Saw Palmetto induced growth arrest of prostate cancer LNCaP, DU145, and PC3 cells with ED50s of approximately
International journal of oncology
PubMed Database
53 Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
Lecouvet, Frédéric E; Geukens, Daphné; Stainier, Annabelle; Jamar, François; Jamart, Jacques; d'Othée, Bertrand Janne; Therasse, Patrick; Berg, Bruno Vande; Tombal, Bertrand; ; 2007-08-01
PURPOSE To evaluate the diagnostic performance, costs, and impact on therapy of one-step magnetic resonance imaging (MRI) of the axial skeleton (MRIas) for detecting bone metastases in patients with high-risk prostate cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed Database
Documents from PubMed Database 53 Results Retrieved
1 Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla, Sanjeev; Maclennan, Gregory T; Hartman, Douglas J; Fu, Pingfu; Resnick, Martin I; Gupta, Sanjay; ; 2007-06-07
Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt/PKB are important signaling ... PI3K-Akt signaling pathway in the invasion of prostate cancer cell lines and activation of this pathway in primary human prostate
International journal of cancer. Journal international du cancer
PubMed Database
2 Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.
Giovannucci, Edward; Liu, Yan; Platz, Elizabeth A; Stampfer, Meir J; Willett, Walter C; ; 2007-04-24
Risk factors for prostate cancer could differ for various sub-groups, such as for "aggressive" and "non-aggressive" cancers or by grade or stage. Determinants of mortality could differ from those for incidence.
International journal of cancer. Journal international du cancer
PubMed Database
3 Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-A new paradigm for cooperation among prostate tumor cells.
Lapouge, Gaëlle; Erdmann, Eva; Marcias, Gemma; Jagla, Monika; Monge, Audrey; Kessler, Pascal; Serra, Sebastian; Lang, Hervé; Jacqmin, Didier; Bergerat, Jean-Pierre; Céraline, Jocelyn; ; 2007-05-31
The emergence of mutations in the androgen receptor (AR) gene is a recurrent event during progression of prostate cancer (PCa) on androgen ablation therapy. In this study, we show that nonsense mutations that lead to carboxyl-terminal end ...
International journal of cancer. Journal international du cancer
PubMed Database
4 Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
Gonzalez-Moreno, Oscar; Segura, Victor; Serrano, Diego; Nguewa, Paul; de Las Rivas, Javier; Calvo, Alfonso; ; 2007-05-24
New therapeutic agents are needed for the treatment of androgen-independent prostate cancer (PrCa). ... methylseleninic acid (MSA) on tumor stage-specific prostate cells derived from the C3 (1)/Tag model for PrCa: Pr111, a slow-growing ...
International journal of cancer. Journal international du cancer
PubMed Database
5 Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition.
Travis, Ruth C; Key, Timothy J; Allen, Naomi E; Appleby, Paul N; Roddam, Andrew W; Rinaldi, Sabina; Egevad, Lars; Gann, Peter H; Rohrmann, Sabine; Linseisen, Jakob; Pischon, Tobias; Boeing, Heiner; Johnsen, Nina Føns; Tjønneland, Anne; Overvad, Kim; Kiem...; 2007-05-22
We examined the hypothesis that serum concentrations of circulating androgens and sex hormone binding globulin (SHBG) are associated with risk for prostate cancer in a case-control study nested ... European Prospective Investigation into Cancer ...
International journal of cancer. Journal international du cancer
PubMed Database
6 Fat and meat intake and prostate cancer risk: The multiethnic cohort study.
Park, Song-Yi; Murphy, Suzanne P; Wilkens, Lynne R; Henderson, Brian E; Kolonel, Laurence N; ; 2007-05-10
Dietary fat and meat as potential risk factors for prostate cancer have been the focus of many epidemiologic investigations, and findings from recent studies in particular have been inconsistent. ... association between these exposures and ...
International journal of cancer. Journal international du cancer
PubMed Database
7 Mechanistic and pharmacodynamic studies of a 25-hydroxyvitamin D(3) derivative in prostate cancer cells.
Lambert, James R; Young, Christian D; Persons, Kelly S; Ray, Rahul; ; 2007-07-31
... has strong antiproliferative effects in cancer cells. But it is highly toxic at therapeutic doses. We have observed that 25-hydroxyvitamin D(3)-3-bromoacetate (25-OH-D(3)-3-BE), a derivative of 25-hydroxyvitamin ... prostate cancer cells.
Biochemical and biophysical research communications
PubMed Database
8 Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano, Giuseppe; De Braud, Filippo; Teresa Sandri, Maria; Renne, Giuseppe; Zorzino, Laura; Scardino, Epifanio; Rocco, Bernardo; Spitaleri, Gianluca; De Pas, Tommaso; Noberasco, Cristina; Nolè, Franco; Verweij, Fabrizio; Matei, Victor; De Cobelli, Ot...; 2007-08-02
We investigated efficacy of gefitinib in hormone-refractory prostate cancer. ... 2004, 23 patients with hormone-refractory prostate cancer were assigned to receive 250 mg oral gefitinib daily in addition to antiandrogen and ...
Anti-cancer drugs
PubMed Database
9 Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Bellmunt, Joaquim; Albiol, Santiago; Albanell, Joan; ; 2007-08-03
BJU international
PubMed Database
10 Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.
Hayes, Julia H; Barry, Michael J; Kantoff, Philip W; Stahl, James E; ; 2007-08-03
BJU international
PubMed Database
11 An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
Dudderidge, Tim; Payne, Heather; Emberton, Mark; ; 2007-06-19
OBJECTIVE To present a management algorithm for men with prostate cancer recurring after external beam radiotherapy (EBRT), based on a review of published reports, to assist clinicians in identifying
BJU international
PubMed Database
12 Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.
Briganti, Alberto; Shariat, Shahrokh F; Chun, Felix K-H; Hutterer, Georg C; Roehrborn, Claus G; Gallina, Andrea; Rigatti, Patrizio; Valiquette, Luc; Montorsi, Francesco; Karakiewicz, Pierre I; ; 2007-06-19
OBJECTIVE To test whether the rate of lymph node invasion (LNI) differs ... PATIENTS AND METHODS In all, 1385 men had RP with bilateral lymphadenectomy for clinically localized prostate cancer (587 from Dallas, Texas and 798 from Milan, Italy).
BJU international
PubMed Database
13 Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Sella, Avishay; Sternberg, Cora; Kovel, Svetlana; Yarom, Nirit; Skoneczna, Iwona; ; 2007-06-15
OBJECTIVE To assess the clinical pattern of progression and prostate-specific antigen doubling time (PSA-DT) after exposure ... cancer (AIPC). PATIENTS AND METHODS Fifty-five patients received docetaxel-based chemotherapy; data were collected ...
BJU international
PubMed Database
14 Does active surveillance for men with localized prostate cancer carry psychological morbidity?
Burnet, Katriina L; Parker, Chris; Dearnaley, David; Brewin, Chris R; Watson, Maggie; ; 2007-06-07
OBJECTIVES To investigate, in a cross-sectional study, the prevalence of anxiety and depression in patients with localised prostate cancer managed by active surveillance, compared with those receiving immediate treatment, as active surveillance ...
BJU international
PubMed Database
15 The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
Roddam, Andrew W; Hamdy, Freddie C; Allen, Naomi E; Price, Christopher P; for the UK Prostate Cancer Risk Management Programme ; 2007-06-05
OBJECTIVE To assess the effects on the performance characteristics, in a prostate-cancer detection programme using prostate-specific antigen (PSA) levels, of a lower PSA threshold and the incorporation of reflex (free or complexed ...
BJU international
PubMed Database
16 Bad expression influences time to androgen escape in prostate cancer.
Teo, Katy; Gemmell, Lisa; Mukherjee, Rono; Traynor, Pamela; Edwards, Joanne; ; 2007-06-05
OBJECTIVE To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation ... is the treatment of choice in advanced prostate ...
BJU international
PubMed Database
17 Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men.
Shimizu, Yousuke; Segawa, Takehiko; Inoue, Takahiro; Shiraishi, Taizo; Yoshida, Toru; Toda, Yoshinobu; Yamada, Tomomi; Kinukawa, Naoko; Terada, Naoki; Kobayashi, Takashi; Kinoshita, Hidefumi; Kamoto, Toshiyuki; Nakamura, Eijiro; Ogawa, Osamu; ; 2007-06-05
OBJECTIVE To investigate the relationship between the expression of Akt (a serine/threonine kinase that plays a central role in tumorigenesis), phosphorylated Akt (p-Akt), prostate cancer tumour grade, androgen receptor (AR)-staining score, ...
BJU international
PubMed Database
18 A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'.
Parker, Chris; ; 2007-05-31
BJU international
PubMed Database
19 Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin.
Li, Hongzhen; Kapur, Aneesh; Yang, Jesse X; Srivastava, Shiv; McLeod, David G; Paredes-Guzman, Julio F; Daugsch, Andreas; Park, Yong K; Rhim, Johng S; ; 2007-08-03
Propolis is a resinous substance collected by bees (Apis mellifera) from ... dracunculifolia), and propolis group 3 on proliferation of metastasis (DU145 and PC-3) and primary malignant tumor (RC58T/h/SA#4)-derived human prostate cancer cells.
International journal of oncology
PubMed Database
20 Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling.
Yang, Yang; Ikezoe, Takayuki; Zheng, Zhixing; Taguchi, Hirokuni; Koeffler, H Phillip; Zhu, Wei-Guo; ; 2007-08-03
PC-SPES is an eight-herb mixture that has an activity against prostate cancer. ... Saw Palmetto induced growth arrest of prostate cancer LNCaP, DU145, and PC3 cells with ED50s of approximately
International journal of oncology
PubMed Database
21 Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells.
Harada, Naoki; Yasunaga, Ryoko; Higashimura, Yasuki; Yamaji, Ryoichi; Fujimoto, Katsumi; Moss, Joel; Inui, Hiroshi; Nakano, Yoshihisa; ; 2007-06-08
Androgen receptor (AR) functions as a transcriptional factor for genes involved in proliferation and differentiation of normal and cancerous prostate cells. Coactivators that bind to AR are required for maximal androgen action.
The Journal of biological chemistry
PubMed Database
22 HPLC for stress-free screening of potential prostate cancer marker catechol estrogens in urine using a diamond-electrode electrochemical and a fluorescence detector.
Katayama, Masatoki Takamatsu, Kiyoshi Kaneko, Satoru Miyaji, Keisuke Ishikawa, Hiromichi Matsuda, Yoshifumi ; 2007-08-03
Improvement of the sensitivity and specificity of a simultaneous stress-free screening method for catechol estrogens as a potential prostate cancer marker ... the sensitivity and specificity of the prostatic
PubMed Database
23 Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins, Scott A; Laxman, Bharathi; Dhanasekaran, Saravana M; Helgeson, Beth E; Cao, Xuhong; Morris, David S; Menon, Anjana; Jing, Xiaojun; Cao, Qi; Han, Bo; Yu, Jindan; Wang, Lei; Montie, James E; Rubin, Mark A; Pienta, Kenneth J; Roulston, Diane; Shah,...; 2007-08-03
Recently, we identified recurrent gene fusions involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, ETV1 or ETV4 in most prostate cancers.
Nature
PubMed Database
24 cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis.
Wu, D; Zhau, H E; Huang, W-C; Iqbal, S; Habib, F K; Sartor, O; Cvitanovic, L; Marshall, F F; Xu, Z; Chung, L W K; ; 2007-02-22
Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP-responsive element-binding protein (CREB) ...
Oncogene
PubMed Database
25 A Refined Comorbidity Measurement Algorithm for Claims-Based Studies of Breast, Prostate, Colorectal, and Lung Cancer Patients.
Klabunde, Carrie N Legler, Julie M Warren, Joan L Baldwin, Laura-Mae Schrag, Deborah ; 2007-05-29
PURPOSE: We evaluated (i) how combining comorbid conditions identified from Medicare inpatient or physician ... linked database, from which four cohorts of cancer patients were derived: breast (n = 26,377), prostate (n = 53,503), colorectal (n
PubMed Database
26 Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.
Lee, Dong I; Sumbilla, Carlota; Lee, Myounghee; Natesavelalar, Chidambaram; Klein, Michael G; Ross, Douglas D; Inesi, Giuseppe; Hussain, Arif; ; 2007-05-04
Cells with increasing resistance to the sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase (SERCA) inhibitor thapsigargin (TG), ranging from 60-fold (PC3/TG(10) cells) ... Thus, novel TG-specific resistance mechanisms are recruited by these cancer cells.
Archives of biochemistry and biophysics
PubMed Database
27 Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer.
Dieli, Francesco; Vermijlen, David; Fulfaro, Fabio; Caccamo, Nadia; Meraviglia, Serena; Cicero, Giuseppe; Roberts, Andrew; Buccheri, Simona; D'Asaro, Matilde; Gebbia, Nicola; Salerno, Alfredo; Eberl, Matthias; Hayday, Adrian C; ; 2007-08-03
The increasing evidence that gammadelta T cells have potent antitumor activity suggests ... trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the gammadelta T-cell agonist zoledronate,
Cancer research
PubMed Database
28 Guggulsterone-Induced Apoptosis in Human Prostate Cancer Cells Is Caused by Reactive Oxygen Intermediate Dependent Activation of c-Jun NH2-Terminal Kinase.
Singh, Shivendra V; Choi, Sunga; Zeng, Yan; Hahm, Eun-Ryeong; Xiao, Dong; ; 2007-08-03
Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, causes apoptosis in cancer cells but ... We now show that guggulsterone-induced cell death in human prostate cancer cells is caused by reactive oxygen intermediate (ROI)-dependent activation of c-Jun NH(2)-terminal kinase (JNK).
Cancer research
PubMed Database
29 Tendon abnormalities mimicking metastatic disease in patients with prostate cancer.
Kerimoglu, Ulku; Kaya, Diana; Ergen, Fatma Bilge; ; 2007-08-02
We present plain x-ray examination, bone scintigraphy, computed tomography, and magnetic resonance imaging of 2 patients diagnosed with prostate cancer who complained of hip pain. Bone scintigraphy was suggestive for metastases.
Clinical nuclear medicine
PubMed Database
30 Blood biomarkers for prostate cancer detection and prognosis.
Shariat, Shahrokh F Karam, Jose A Roehrborn, Claus G ; 2007-07-31
Prostate cancer is the most noncutaneous malignancy diagnosed in men in the USA. The discovery of prostate-specific antigen (PSA) revolutionized prostate cancer diagnosis and management in the 1990s.
PubMed Database
31 Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor.
Pickles, Tom; ; 2007-07-31
Evaluation of: Freedland SJ, Humphreys EB, Mangold LA et al.: Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause ...
Future oncology (London, England)
PubMed Database
32 Pectin induces apoptosis in human prostate cancer cells: correlation of apoptotic function with pectin structure.
Jackson, Crystal L; Dreaden, Tina M; Theobald, Lisa K; Tran, Nhien M; Beal, Tiffany L; Eid, Manal; Gao, Mu Yun; Shirley, Robert B; Stoffel, Mark T; Kumar, M Vijay; Mohnen, Debra; ; 2007-05-22
Treatment options for androgen-independent prostate cancer cells are limited. Therefore, it is critical to identify agents that induce death of both androgen-responsive and androgen-insensitive cells.
Glycobiology
PubMed Database
33 Stem cells in prostate cancer initiation and progression.
Lawson, Devon A; Witte, Owen N; ; 2007-08-03
... paradigm shift in our understanding of cancer as a disease of stem cells. This Review focuses on the application of these concepts to investigation of the role of stem cells in prostate cancer initiation and progression.
The Journal of clinical investigation
PubMed Database
34 Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai, Tommaso; Bartoletti, Riccardo; ; 2007-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed Database
35 Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.
Lecouvet, Frédéric E; Geukens, Daphné; Stainier, Annabelle; Jamar, François; Jamart, Jacques; d'Othée, Bertrand Janne; Therasse, Patrick; Berg, Bruno Vande; Tombal, Bertrand; ; 2007-08-01
PURPOSE To evaluate the diagnostic performance, costs, and impact on therapy of one-step magnetic resonance imaging (MRI) of the axial skeleton (MRIas) for detecting bone metastases in patients with high-risk prostate cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PubMed Database
36 Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer.
Brown, Duncan J F; McArthur, Dorothy; Moulsdale, Helen; ; 2007-07-03
Journal of pain and symptom management
PubMed Database
37 Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes.
Gudmundsson, Julius; Sulem, Patrick; Steinthorsdottir, Valgerdur; Bergthorsson, Jon T; Thorleifsson, Gudmar; Manolescu, Andrei; Rafnar, Thorunn; Gudbjartsson, Daniel; Agnarsson, Bjarni A; Baker, Adam; Sigurdsson, Asgeir; Benediktsdottir, Kristrun R; Jako...; 2007-07-03
We performed a genome-wide association scan to search for sequence variants conferring risk of prostate cancer using 1,501 Icelandic men with prostate cancer and 11,290 controls. Follow-up studies involving three additional ...
Nature genetics
PubMed Database
38 Prostate cancer screening an individual decision.
Holcomb, Susan Simmons; ; 2007-08-02
The Nurse practitioner
PubMed Database
39 [Imaging procedures to diagnose prostate cancer.]
Seitz, M Scher, B Scherr, M Tilki, D Schlenker, B Gratzke, C Schipf, A Stanislaus, P Müller-Lisse, U Reich, O Stief, C ; 2007-08-01
Prostate cancer is one of the most frequent malignant diseases in men. ... progress achieved in imaging procedures, prostate biopsy is the gold standard for diagnosing prostate cancer.
PubMed Database
40 Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.
Pickles, Tom Ruether, J Dean Weir, Lorna Carlson, Linda Jakulj, Fabijana the SCRN Communication Team† ; 2007-05-30
OBJECTIVES To review the psychosocial needs of men undergoing active surveillance (AS, the monitoring of early prostate cancer, with curative intervention only if the disease significantly progresses) for prostate cancer, ...
PubMed Database
41 Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer.
Tam, L; McGlynn, L M; Traynor, P; Mukherjee, R; Bartlett, J M S; Edwards, J; ; 2007-06-28
The main cause of prostate cancer-related mortality is the development of hormone-refractory disease. ... IL-6 are raised in hormone-refractory prostate cancer patients and evidence from cell line studies suggests that the ...
British journal of cancer
PubMed Database
42 Association between FAS polymorphism and prostate cancer development.
Lima, L Morais, A Lobo, F Calais-da-Silva, F M Calais-da-Silva, F E Medeiros, R ; 2007-08-02
The role of FAS polymorphisms in prostate cancer has not been studied. ... -670 genotypes in DNA from 904 men: 657 prostate ... inhibition caused by the soluble form.Prostate Cancer and Prostatic Diseases
PubMed Database
43 Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer.
Halabi, Susan Ou, San-San Vogelzang, Nicholas J Small, Eric J ; 2007-08-01
BACKGROUND.: Obesity has a variety of adverse health outcomes, but to the authors' knowledge, the effect of obesity on outcome in patients with advanced prostate cancer is not known. ... with metastatic, castration-recurrent prostate ...
PubMed Database
44 A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Gross, Mitchell Higano, Celestia Pantuck, Allan Castellanos, Olga Green, Erica Nguyen, Koo Agus, David B ; 2007-07-31
ABSTRACT: BACKGROUND: Docetaxel is the standard first-line agent for the treatment of androgen-independent prostate cancer (AIPC). ... toxicity of cytotoxic chemotherapy for prostate cancer.
PubMed Database
45 Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal, Christopher S Gore, John L Krupski, Tracey L Hanley, Janet Schonlau, Matthias Litwin, Mark S And the Urologic Diseases in America Project ; 2007-07-28
BACKGROUND.: The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. ... common reason for death among men with prostate cancer who do not die of the disease itself, data ...
PubMed Database
46 The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy.
Vickers, Andrew J Ulmert, David Serio, Angel M Björk, Thomas Scardino, Peter T Eastham, James A Berglund, Göran Lilja, Hans ; 2007-07-28
Both benign and malignant prostate diseases elevate total prostate-specific antigen (tPSA), and the incidence of ... fPSA, tPSA and hK2 were measured in archived plasma collected during 1974-1986 in 501 men subsequently diagnosed with prostate cancer up to 1999 and in 1,292 matched controls.
PubMed Database
47 The androgen receptor and prostate cancer: A role for sexual selection and sexual conflict?
Summers, Kyle Crespi, Bernard ; 2007-07-28
We propose and evaluate the hypothesis that the CAG repeat region of the androgen receptor represents a locus ... However, short repeats are also associated with increased risk of prostate cancer, and with more aggressive forms of the disease.
PubMed Database
48 IS OBESITY A RISK FACTOR FOR PROSTATE CANCER?
Goldstraw, Miles A Besrani, Dler Amoroso, Peter Kirby, Roger S ; 2007-07-31
PubMed Database
49 Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients.
Ismail, Mohamed Ahmed, Shwan Kastner, Christof Davies, John ; 2007-07-31
OBJECTIVE To report the short- to intermediate-term experience of using salvage targeted cryoablation of the prostate (TCAP) for the recurrence of localized prostate cancer after radiotherapy.
PubMed Database
50 The role of intermittent androgen deprivation in prostate cancer.
Boccon-Gibod, Laurent Hammerer, Peter Madersbacher, Stephan Mottet, Nicolas Prayer-Galetti, Tommaso Tunn, Ulf ; 2007-07-31
PubMed Database
51 Targeting uPA/uPAR in prostate cancer.
Li, Y Cozzi, P J ; 2007-07-31
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease ...
PubMed Database
52 PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer.
Ganzer, Roman Rogenhofer, Sebastian Walter, Bernhard Lunz, Jens-Claudio Schostak, Martin Wieland, Wolf F Blana, Andreas ; 2007-07-31
OBJECTIVES: To assess if prostate-specific antigen (PSA) nadir is an independent predictor of treatment failure and disease-free ... (Ablatherm((R)), EDAP, Lyon, France) for localised prostate cancer without previous hormonal therapy were evaluated retrospectively.
PubMed Database
53 Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer.
Doak, Shareen H; Jenkins, Spencer A; Hurle, Rhidian A; Varma, Murali; Hawizy, Azad; Kynaston, Howard G; Parry, James M; ; 2007-07-28
Abnormal expression of bone morphogenic proteins (BMP) has been reported in prostate cancer as compared to benign prostatic tissue. ... this possibility in patients with early prostate cancer.
Cancer genetics and cytogenetics
PubMed Database